# CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

> **NCT02678338** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 20 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Hu5F9-G4

## Key facts

- **NCT ID:** NCT02678338
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-11
- **Final completion:** 2019-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02678338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02678338, "CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02678338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*